Target intelligence / Profile preview

Leucine-rich repeat-containing 37B pseudogene (LRRC37BP)

Target
LRRC37BP
Molecular classification
Other (Pseudogene)
01

Overview

Leucine-rich repeat-containing 37B pseudogene (often referred to as LRRC37BP1, LRRC37B2, or just LRRC37B pseudogene) is a **pseudogene** in the human genome. Pseudogenes are nonfunctional copies of genes that have accumulated disabling mutations, such as frameshifts or premature stop codons, rendering them incapable of producing functional proteins[2][5][6]. The LRRC37 family contains functional paralogs—such as LRRC37B—that are protein coding, but this pseudogene variant does not code for a functional protein and shows no evidence of direct biological activity or involvement in diseases. Pseudogenes may retain sequence similarity to their ancestral functional genes but are not considered therapeutic targets or active molecular participants in cellular pathways. Their main relevance is in genome annotation, evolutionary studies, or as potential sources of regulatory RNA, but there is currently *no evidence* implicating "leucine-rich repeat-containing 37B pseudogene" in therapeutic targeting, drug interactions, disease mechanisms, or as a biomarker[2][5][6]. **Additional context:** - Pseudogenes can sometimes interfere with molecular genetic assays (e.g., PCR amplification bias) but do not encode active proteins or serve as drug targets[2][5]. - Confusion occasionally occurs between pseudogenes and their functional gene paralogs (e.g., LRRC37B), which should not be conflated. The ENSG00000273609 entry, as specified, refers to a pseudogene, not the protein-coding LRRC37B[6]—**which is a separate entity altogether and is also not recognized as a therapeutic target.** - If a therapeutic or experimental context refers to LRRC37B as a target, the pseudogene entry should be corrected to point to the functional protein-coding gene rather than the pseudogene. **In summary:** ENSG00000273609 is a **pseudogene** with no known protein product, biological function, druggability, or disease role, so it is not considered a therapeutic target, and its entry as such is likely either incorrect or a misannotation[2][5][6].

Other names
LRRC37BP1LRRC37B pseudogene 1LRRC37B2
02

Mechanism of action

None applicable

03

Biological functions

None (pseudogene; no known protein product or function)
04

Disease associations

None known (pseudogene; not associated with disease causation or therapeutic targeting)
05

Safety considerations

None (pseudogene; not a therapeutic target)
06

Interacting drugs

None (pseudogene and therefore not a druggable target)
07

Biomarkers

None currently established

Beyond the preview

Go deeper on Leucine-rich repeat-containing 37B pseudogene (LRRC37BP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leucine-rich repeat-containing 37B pseudogene (LRRC37BP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call